ResMed Q4 Fiscal Year 2026 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $1.5 billion, a 9% increase year-over-year (8% on a constant-currency basis).

Non-GAAP EPS: Increased by 16% to $2.95.

Full Year Revenue Growth: 10% headline growth and 8% on a constant-currency basis for FY 2026.

Free Cash Flow: Over $1.6 billion for the fiscal year.

Gross Margin: 62.3% in Q4, up 90 basis points year-over-year.

Operating Margin: 35.2%, down 10 basis points year-over-year.

Shareholder Returns: Over $1 billion returned through buybacks and dividends, a 72% increase from the previous year.

2Strategic Updates and Business Highlights

Digital Health Ecosystem: Continued focus on enhancing the digital health ecosystem for sleep and breathing health.

Partnerships: Successful collaboration with Oura, leading to increased user engagement and early identification of undiagnosed sleep issues.

Product Launches: Introduction of AirSense 11 and AirCurve 11 platforms, with ongoing global rollout and expansion into new markets.

Acquisitions: Completed the acquisition of Noctrix to enhance offerings for restless legs syndrome (RLS) and announced the divestiture of MatrixCare to sharpen focus on core sleep and breathing health areas.

Innovation: Significant investment in R&D, with a 22% increase in R&D expenses in Q4, aimed at developing next-gen devices and AI-driven solutions.

3Forward Guidance and Outlook

FY 2027 Revenue Growth: Expected to be in the range of 5% to 7%, with a reported revenue target of $5.75 billion to $5.85 billion.

Non-GAAP EPS Guidance: Projected between $12.00 and $12.25, reflecting a 7% to 10% increase year-over-year.

Gross Margin Expansion: Anticipated low double-digit growth in gross margin for FY 2027.

Shareholder Returns: Planned return of over $1.85 billion to shareholders, including a 10% increase in dividends to $0.66 per share.

4Bad News, Challenges, or Points of Concern

Field Safety Notice: A $42 million provision taken for expected costs related to the Astral device field safety notice, with a $75 million revenue headwind expected in FY 2027 due to the suspension of Astral sales.

Life Support Device Revenue Decline: Significant declines in life support device revenue, down 45% in the Americas and 38% internationally.

Inflationary Pressures: Ongoing inflation affecting costs, particularly in electronic components and freight, impacting gross margins.

Market Dynamics: Competitive pressures in the sleep device market, particularly from new entrants and existing competitors.

5Notable Q&A Insights

Gross Margin Concerns: Management acknowledged a sequential decline in gross margin due to inflationary pressures and indicated that modest price increases would be implemented to offset these costs.

Revenue Guidance Clarification: The guidance for 5% to 7% revenue growth includes a significant headwind from the Astral situation, with core growth potentially exceeding 6% to 8% when excluding this impact.

M&A Strategy: Management indicated a focus on tuck-in acquisitions in the $100 million to $500 million range, emphasizing strategic fit and ROI metrics.

GLP-1 Impact: Early data on oral GLP-1s shows lower adherence compared to injectables, but overall awareness and demand generation for sleep health remain strong. This summary captures the key aspects of ResMed's Q4 FY 2026 earnings call, highlighting both the achievements and the challenges faced by the company as it navigates a complex market landscape.